Results: Osseous metastases develop in close to 90% of patients with metastatic prostate
cancer, thus making bone scans (single photon, using Tc-99m labeled phosphonates) the …

Background Clinical applicability of newly discovered reagents for molecular imaging is
hampered by the lack of translational models. As the dog prostate cancer (DPC-1) model …

Background: Considering the non-invasive nature of magnetic resonance spectroscopy
(MRS) and its ability to detect prostate lesions, the present study aimed to investigate the …

Conventional imaging modalities (CIM) have limited sensitivity and specificity for detection of
metastatic prostate cancer. We examined the potential of a first-in-class radiofluorinated …

Aim: This study attempted to ascertain the utility of 18 F-FCH PET/CT as a first-line
investigation in preoperative localization of abnormal parathyroid tissue in primary …

Controversy surrounds the benefit of whole pelvis radiotherapy (WPRT) over prostate-only
radiotherapy (PORT) for intermediate-risk and high-risk patients with prostate cancer. In the …

Bone is among the most common locations of metastasis, and therefore represents an
important clinical target for diagnosis and follow-up in patients with cancer. Bone metastases …

IJMS | Free Full-Text | Molecular Research in Urology 2014: Update on PET/MR Imaging of
the Prostate Next Article in Journal Effects of Lead on the Morphology and Structure of the …

Purpose: To investigate the associations of metabolite levels derived from magnetic
resonance spectroscopic imaging (MRSI) and 18F-fluciclovine positron emission …

Interventions: Diffuse bone and liver metastases were 68 gallium-DOTATOC PET-positive
with only mild uptake on 18 FDG PET/CT. An increased prostate specific antigen (8 μg/L) …